Table 1.
Comparison of demographic and clinicopathological features among patients with different F-NLRs
| Features | F-NLR
|
All (N=693) | P-value* | ||
|---|---|---|---|---|---|
| 0 (n=181) | 1 (n=295) | 2 (n=217) | |||
|
| |||||
| Gender | 0.523 | ||||
| Male | 114 (63%) | 185 (62.7%) | 146 (67.3%) | 445 (64.2%) | |
| Female | 67 (37%) | 110 (37.3%) | 71 (32.7%) | 248 (35.8%) | |
| Age (years) | 0.001 | ||||
| ≤60 | 127 (70.2%) | 154 (52.2%) | 125 (57.6%) | 406 (58.6%) | |
| >60 | 54 (29.8%) | 141 (47.8%) | 92 (42.4%) | 287 (41.4%) | |
| Differentiation | 0.052 | ||||
| Well | 12 (6.6%) | 22 (7.5%) | 11 (5.1%) | 45 (6.5%) | |
| Moderate | 130 (71.8%) | 211 (71.5%) | 137 (63.1%) | 478 (69%) | |
| Poor | 31 (17.1%) | 39 (13.2%) | 45 (20.7%) | 115 (16.6%) | |
| Unknown | 8 (4.4%) | 23 (7.8%) | 24 (11.1%) | 55 (7.9%) | |
| Histological type | 0.043 | ||||
| Adenocarcinoma | 163 (90.1%) | 244 (82.7%) | 177 (81.6%) | 584 (84.3%) | |
| Mucinous type | 18 (9.9%) | 51 (17.3%) | 40 (18.4%) | 109 (15.7%) | |
| T stage | 0.034 | ||||
| 1–2 | 31 (17.1%) | 42 (14.2%) | 16 (7.4%) | 89 (12.8%) | |
| 3 | 49 (27.1%) | 84 (28.5%) | 58 (26.7%) | 191 (27.6%) | |
| 4 | 101 (55.8%) | 169 (57.3%) | 143 (65.9%) | 413 (59.6%) | |
| N stage | 0.652 | ||||
| 0 | 98 (54.1%) | 139 (47.1%) | 104 (47.9%) | 341 (49.2%) | |
| 1 | 45 (24.9%) | 86 (29.2%) | 63 (29%) | 194 (28%) | |
| 2 | 38 (21%) | 70 (23.7%) | 50 (23%) | 158 (22.8%) | |
| TNM stage | 0.021 | ||||
| 1 | 27 (14.9%) | 25 (8.5%) | 12 (5.5%) | 64 (9.2%) | |
| 2 | 71 (39.2%) | 113 (38.3%) | 92 (42.4%) | 276 (39.8%) | |
| 3 | 83 (45.9%) | 157 (53.2%) | 113 (52.1%) | 353 (50.9%) | |
| Morphology | 0.026 | ||||
| Expansive | 27 (14.9%) | 64 (21.7%) | 25 (11.5%) | 116 (16.7%) | |
| Infiltrative | 3 (1.7%) | 11 (3.7%) | 7 (3.2%) | 21 (3%) | |
| Ulcerative | 149 (82.3%) | 217 (73.6%) | 179 (82.5%) | 545 (78.6%) | |
| Complex | 2 (1.1%) | 3 (1%) | 6 (2.8%) | 11 (1.6%) | |
| Location | 0.015 | ||||
| RCC | 17 (9.4%) | 51 (17.3%) | 40 (18.4%) | 108 (15.6%) | |
| LCC | 37 (20.4%) | 61 (20.7%) | 58 (26.7%) | 156 (22.5%) | |
| RECC | 127 (70.2%) | 183 (62%) | 119 (54.8%) | 429 (61.9%) | |
| Tumor size | 0.016 | ||||
| ≤4 cm | 90 (49.7%) | 123 (41.7%) | 72 (33.2%) | 285 (41.1%) | |
| >4 cm | 86 (47.5%) | 158 (53.6%) | 132 (60.8%) | 376 (54.3%) | |
| Unknown | 5 (2.8%) | 14 (4.7%) | 13 (6%) | 32 (4.6%) | |
| Venous invasion | 0.693 | ||||
| Positive | 9 (5%) | 10 (3.4%) | 9 (4.1%) | 28 (4%) | |
| Negative | 172 (95%) | 285 (96.6%) | 208 (95.9%) | 665 (96%) | |
| Perineural invasion | 0.595 | ||||
| Positive | 5 (2.8%) | 10 (3.4%) | 10 (4.6%) | 25 (3.6%) | |
| Negative | 176 (97.2%) | 285 (96.6%) | 207 (95.4%) | 668 (96.4%) | |
| Tumor deposits | 0.295 | ||||
| Present | 5 (2.8%) | 17 (5.8%) | 9 (4.1%) | 31 (4.5%) | |
| Absent | 176 (97.2%) | 278 (94.2%) | 208 (95.9%) | 662 (95.5%) | |
| Chemotherapy | 0.768 | ||||
| Yes | 143 (79%) | 234 (79.3%) | 177 (81.6%) | 554 (79.9%) | |
| No | 38 (21%) | 61 (20.7%) | 40 (18.4%) | 139 (20.1%) | |
Notes:
*
P-values were calculated by the chi-squared test or the Fisher’s exact test. P-value for significance was <0.05.
Abbreviations: LCC, left colon cancer; NLR, neutrophil–lymphocyte ratio; F-NLR, combined fibrinogen and NLR; RCC, right colon cancer; RECC, rectal cancer.